All‐cause mortality: range 1 mo to 1 y · adults admitted to the ICU
It is very uncertain whether higher changes all‐cause mortality: range 1 mo to 1 y compared with lower FiO2 or targets of arterial oxygenation (very low certainty).
1 finding from 1 review
All-cause mortality (ACM) · Adults (any age) with a known number of remaining teeth, followed prospectively in cohort studies
Each additional lost tooth was associated with a multivariable-adjusted HR of 1.02 (95% CI 1.01 to 1.03) for all-cause mortality (11 studies, I2=89%), statistically significant; GRADE per-analysis ratings reported in Supplementary File 7 (not available in provided sources).
3 findings from 1 review
All‐cause mortality · people hospitalised with COVID‐19
Higher‐dose anticoagulants showed no clear difference in all‐cause mortality compared with lower‐dose anticoagulants (high certainty).
1 finding from 1 review
All‐cause mortality Study duration range 12‐96 months Omega‐6 dose range 1.5%‐24.5% E · adults with or without existing CVD
Higher showed no clear difference in all‐cause mortality Study duration range 12‐96 months Omega‐6 dose… compared with lower omega‐6: primary outcomes (low certainty).
1 finding from 1 review
All‐cause mortality · people with or without existing CVD, men and women
Higher polyunsaturated fatty acid (PUFA) showed no clear difference in all‐cause mortality compared with lower PUFA (moderate certainty).
1 finding from 1 review
All‐cause mortality · older adults with primary hypertension
Higher BP target (< 150‐160/95‐105 mmHg) showed no clear difference in all‐cause mortality compared with lower BP target (< 140/90 mmHg) (low certainty).
1 finding from 1 review
All cause mortality · people with chronic kidney disease (predialysis (GFR 15 to 60 mL/min/1.73 m²), HD, PD, transplant recipients)
Meta-analysis of observational studies (higher vs lower 25(OH)D) for All cause mortality, Patients with chronic kidney disease: RR 0.86 (95% CI 0.81 to 0.92), statistically significant. Umbrella review outcome-level evidence grade: No conclusion.
1 finding from 1 review
All cause mortality · Adults (general population)
Meta-analysis of observational studies (higher vs lower 25(OH)D) for All cause mortality: HR 0.72 (95% CI 0.66 to 0.78), statistically significant. Umbrella review outcome-level evidence grade: No conclusion.
1 finding from 1 review
All cause mortality (in CKD patients) · Participants in observational studies
The meta-analysis of observational studies reported a RR of 0.88 (95% CI 0.81 to 0.93) for higher versus lower circulating vitamin D concentration.
1 finding from 1 review
All‐cause mortality up to 30 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
Summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) showed no clear difference in all‐cause mortality up to 30 days compared with low‐dose dexamethasone (6 mg to 8 mg) (low certainty).
1 finding from 1 review
All‐cause mortality up to 120 days · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
It is very uncertain whether summary of findings table ‐ High‐dose dexamethasone (12 mg or higher) changes all‐cause mortality up to 120 days compared with low‐dose dexamethasone (6 mg to 8 mg) (very low certainty).
1 finding from 1 review